Filtered By:
Specialty: Drugs & Pharmacology
Countries: China Health
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Efficacy and Safety of Xingnaojing Injection for Emergency Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Conclusion: XNJ appears to be effective and safe for emergency treatment of AIS. The first 72 h after the onset of stroke, in particular the first 6 hours, may be the optimum initiation time. However, further high-quality RCTs are warranted to determine an appropriate initiation time.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=233211], identifier [CRD42021233211].
Source: Frontiers in Pharmacology - March 24, 2022 Category: Drugs & Pharmacology Source Type: research
A Network-Based Approach to Investigate the Neuroprotective Effects and Mechanisms of Action of Huangqi-Chuanxiong and Sanleng-Ezhu Herb Pairs in the Treatment of Cerebral Ischemic Stroke
Conclusion: We identified a new treatment formulation for ischemic stroke by data mining and network pharmacological target prediction. The beneficial effects of the new formulation act by regulating multiple target genes and pathways. The mechanism of action of the new formulation may be related to the AKT and ERK signaling pathways. Our findings provide a theoretical basis for the effects of the new formulation on ischemic stroke injury.
Source: Frontiers in Pharmacology - March 23, 2022 Category: Drugs & Pharmacology Source Type: research
Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack
Conclusions: The results indicated that early treatment with a 30-days ticagrelor plus aspirin for an acute mild-to-moderate IS or TIA is highly cost-effective in a Chinese setting.
Source: Frontiers in Pharmacology - March 18, 2022 Category: Drugs & Pharmacology Source Type: research
The Efficacy and Safety of Ginkgo Terpene Lactone Preparations in the Treatment of Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Conclusion: Ginkgo terpene lactone preparations have good therapeutic effects on patients with IS. For acute IS, ginkgo diterpene lactone meglumine injection can be used as a complementary therapy to improve the clinical efficacy of rt-PA.
Source: Frontiers in Pharmacology - March 18, 2022 Category: Drugs & Pharmacology Source Type: research
Elucidating the Synergistic Effect of Multiple Chinese Herbal Prescriptions in the Treatment of Post-stroke Neurological Damage
Conclusion: By integrating pharmacological and chemoinformatic approaches, our study provides a new method for identifying the effective synergistic compounds of TCM prescriptions. The filtered compounds and their synergistic effects on stroke require further research.
Source: Frontiers in Pharmacology - March 9, 2022 Category: Drugs & Pharmacology Source Type: research
GC-MS Profile of Hua-Feng-Dan and RNA-Seq Analysis of Induced Adaptive Responses in the Liver
Conclusion: GC-MS primarily profiled volatile and liposoluble components in Hua-Feng-Dan. Hua-Feng-Dan at the hepatoprotective dose did not produce liver pathological changes but induced metabolic and signaling pathway activations. The effects of Hua-Feng-Dan on liver transcriptome changes point toward induced adaptive responses to program the liver to produce hepatoprotective effects.
Source: Frontiers in Pharmacology - March 8, 2022 Category: Drugs & Pharmacology Source Type: research
Bibliometric Analysis of Ferroptosis in Stroke From 2013 to 2021
Conclusion: Further exploration of the mechanisms of crosstalk between ferroptosis and other programmed cell death may improve clinical applications and therapeutic effects against stroke. Scholars will also continue to pay attention to and be interested in the hot topic “ferroptosis in stroke”, to produce more exciting results and provide new insights into the bottleneck of stroke treatment.
Source: Frontiers in Pharmacology - February 21, 2022 Category: Drugs & Pharmacology Source Type: research
Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: Applications for natural compounds from medicinal herbs
Biomed Pharmacother. 2022 Feb 12;148:112719. doi: 10.1016/j.biopha.2022.112719. Online ahead of print.ABSTRACTNeuroprotective and neurorestorative therapy represent two major drug intervention strategies for ischemic stroke. Multiple factors such as excitotoxicity, inflammation, angiogenesis, and neurogenesis are the main pathological processes that underlie acute and chronic ischemic brain injury. Furthermore, their intimate interactions mediate blood-brain barrier permeability, increase neurovascular unit structural damage as well as a hemorrhagic transformation during ischemic stroke. We aimed to review the current unde...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 15, 2022 Category: Drugs & Pharmacology Authors: Ting Zhu Lei Wang Li-Ping Wang Qi Wan Source Type: research
Folium < em > Ginkgo < /em > extract and tetramethylpyrazine sodium chloride injection (Xingxiong injection) protects against focal cerebral ischaemia/reperfusion injury via activating the Akt/Nrf2 pathway and inhibiting NLRP3 inflammasome activation
CONCLUSIONS: Xingxiong injection prevents cerebral ischaemia/reperfusion injury via activating the Akt/Nrf2 pathway and inhibiting NLRP3 inflammasome. These findings provide experimental evidence for clinical use of drugs in the treatment of ischaemic stroke.PMID:35060427 | PMC:PMC8786246 | DOI:10.1080/13880209.2021.2014895
Source: Pharmaceutical Biology - January 21, 2022 Category: Drugs & Pharmacology Authors: Ting Zhu Bin-Yu Fang Xiang-Bao Meng Shu-Xia Zhang Hong Wang Ge Gao Fei Liu Yu Wu Jin Hu Gui-Bo Sun Xiao-Bo Sun Source Type: research
Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury
Cerebral ischemic reperfusion injury (CI/RI) is a critical factor that leads to a poor prognosis in patients with ischemic stroke. It is an extremely complicated pathological process that is clinically characterized by high rates of disability and mortality. Current available treatments for CI/RI, including mechanical and drug therapies, are often accompanied by significant side effects. Therefore, it is necessary to discovery new strategies for treating CI/RI. Many studies confirm that Chinese herbal medicine (CHM) was used as a potential drug for treatment of CI/RI with the advantages of abundant resources, good efficacy...
Source: Frontiers in Pharmacology - January 17, 2022 Category: Drugs & Pharmacology Source Type: research
Neuroprotective Effect of Daidzein Extracted From Pueraria lobate Radix in a Stroke Model Via the Akt/mTOR/BDNF Channel
Daidzein is a plant isoflavonoid primarily isolated from Pueraria lobate Radix as the dry root of P. lobata (Wild.) Ohwi, have long been used as nutraceutical and medicinal herb in China. Despite the report that daidzein can prevent neuronal damage and improve outcome in experimental stroke, the mechanisms of this neuroprotective action have been not fully elucidated. The aim of this study was to determine whether the daidzein elicits beneficial actions in a stroke model, namely, cerebral ischemia/reperfusion (I/R) injury, and to reveal the underlying neuroprotective mechanisms associated with the regulation of Akt/mTOR/BD...
Source: Frontiers in Pharmacology - January 14, 2022 Category: Drugs & Pharmacology Source Type: research
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis
CONCLUSION: Genotype-guided antiplatelet treatment could reduce the risk of MACEs without increasing the risk of bleeding events as compared with the standard treatment in patients with CAD or those undergoing PCI. In addition, Genotype-guided antiplatelet treatment might benefit Chinese population or patients with ACS.PMID:34995471 | DOI:10.18433/jpps32140
Source: Journal of Pharmacy and Pharmaceutical Sciences - January 7, 2022 Category: Drugs & Pharmacology Authors: Borui Tang Xin Wang Xinrui Wang Lihong Liu Zhuo Ma Source Type: research
